

Revvity introduces new workflow to accelerate newborn sequencing research

15 March 2024 | News

Designed to build the foundation for diagnosing rare diseases in the future



American firm Revvity, Inc. has announced the introduction of a flexible end-to-end workflow solution for newborn research, enabling users to utilise different instruments, reagents and databases based on a lab's needs.

The research-use only (RUO) offering from Revvity culminates in analysis and report, covering essential steps in the sequencing process. The solution enables identification of variants in more than 350 genes, complemented by a large database of carefully pre-curated variants.

The offering includes dried blood spot collection and processing devices, Chemagic[™] kits and instruments for nucleic acid extraction, liquid handlers and reagents for library preparation, VICTOR2[™] D Instrument for sample quality control, and software capabilities. The workflow is compatible with the Element AVITI[™] system and other leading NGS platforms.

For labs interested in outsourcing the workflow, Revvity's Clinical Genomic Services provides solutions from delivery of a sample collection kit to final report, or the flexibility to access sequence data or report only to augment the customer's inhouse capabilities.